Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 1
2012 1
2013 3
2014 2
2016 2
2017 1
2018 1
2020 1
2021 1
2023 1
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis.
Mao M, Wang M, Yu Q, Chen Q, Zhu H, Wan T, Yang Y, Zhao J. Mao M, et al. J Affect Disord. 2025 Dec 1;390:120064. doi: 10.1016/j.jad.2025.120064. Epub 2025 Aug 13. J Affect Disord. 2025. PMID: 40816367
OBJECTIVE: This study aims to use the Food and Drug Administration Adverse Event Reporting System (FAERS) to identify medications linked to memory disorders and to offer updated insights into medication-induced memory disorders. METHODS: We analyzed adverse event (AE) repo …
OBJECTIVE: This study aims to use the Food and Drug Administration Adverse Event Reporting System (FAERS) to identify medications linked to …
An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system.
Tang L, Li Q, Zhao X, Ding L, Li H, Ding C, Teng L. Tang L, et al. Sci Rep. 2025 Jul 1;15(1):21295. doi: 10.1038/s41598-025-06403-0. Sci Rep. 2025. PMID: 40594326 Free PMC article.
Food and Drug Administration's Adverse Event Reporting System (FAERS), a comprehensive real-world investigation of drug-induced psychiatric disorders in children and adolescents is conducted. We reviewed all adverse event (AE) reports related to mental disorders in childre …
Food and Drug Administration's Adverse Event Reporting System (FAERS), a comprehensive real-world investigation of drug-induced psychiatric …
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
Olabi B, Worboys S, Garland T, Grindlay DJC, Rogers NK, Harman KE. Olabi B, et al. Clin Exp Dermatol. 2020 Dec;45(8):980-985. doi: 10.1111/ced.14304. Epub 2020 Jun 22. Clin Exp Dermatol. 2020. PMID: 32568435 Free article.
The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. In total, 17 SRs on various systemic treatments used in AE were first published or indexed in 2018. There is a lack of evidence to s …
The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. …
Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system.
Ou Z, Han Y, Zhuang W, Xiao Y, Cai S, Zhang X. Ou Z, et al. Int J Clin Pharmacol Ther. 2024 Nov;62(11):497-506. doi: 10.5414/CP204560. Int J Clin Pharmacol Ther. 2024. PMID: 39099387
The United States Food and Drug Administration (FDA) has been warning about the psychiatric disorders associated with montelukast (MTK) for years. To study the characteristics of the presence of MTK-associated adverse events (AEs), we obtained data from the FDA Adverse Eve …
The United States Food and Drug Administration (FDA) has been warning about the psychiatric disorders associated with montelukast (MT …
Use of antioxidants in urinary tract infection.
Allameh Z, Salamzadeh J. Allameh Z, et al. J Res Pharm Pract. 2016 Apr-Jun;5(2):79-85. doi: 10.4103/2279-042X.179567. J Res Pharm Pract. 2016. PMID: 27162800 Free PMC article. Review.
Antioxidants used for this condition were Vitamins A, E, and C, cytoflavin, caffeic acid phenethyl ester, ebselen, allopurinol, melatonin, N-acetylcysteine, oleuropein, montelukast, oxytocin, ozon, dapsone, pentoxifyllin, tadalafil, bilirubin, cranberry, meloxicam, L-carni …
Antioxidants used for this condition were Vitamins A, E, and C, cytoflavin, caffeic acid phenethyl ester, ebselen, allopurinol, melatonin, N …
A Longitudinal Analysis of Black Box Warnings: Trends and Implications for Drug Safety.
Rajendran Y, Kondampati N, Eerike M, Mali K, Francis C L. Rajendran Y, et al. Cureus. 2024 Apr 4;16(4):e57597. doi: 10.7759/cureus.57597. eCollection 2024 Apr. Cureus. 2024. PMID: 38706997 Free PMC article. Review.
Awareness of these warnings is essential to prevent adverse effects and enhance patient care, especially concerning drugs like guaifenesin/hydrocodone bitartrate, zolpidem, and montelukast commonly encountered in clinical practice....
Awareness of these warnings is essential to prevent adverse effects and enhance patient care, especially concerning drugs like guaifenesin/h …
Reports of suicidality in clinical trials of montelukast.
Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Philip G, et al. J Allergy Clin Immunol. 2009 Oct;124(4):691-6.e6. doi: 10.1016/j.jaci.2009.08.010. J Allergy Clin Immunol. 2009. PMID: 19815114
Summaries were constructed from investigator-reported AE terms possibly related to suicidality (completed suicide, suicide attempt, and suicidal ideation) or self-injurious behavior. ...For the descriptive review, 20,131 adults and children received montelukast, 9,2 …
Summaries were constructed from investigator-reported AE terms possibly related to suicidality (completed suicide, suicide attempt, a …
Evaluation of Montelukast for the Treatment of Children With Japanese Cedar Pollinosis Using an Artificial Exposure Chamber (OHIO Chamber).
Hashiguchi K, Okubo K, Inoue Y, Numaguchi H, Tanaka K, Oshima N, Mehta A, Nishida C, Saito I, Philip G. Hashiguchi K, et al. Allergy Rhinol (Providence). 2018 Jul 13;9:2152656718783599. doi: 10.1177/2152656718783599. eCollection 2018 Jan-Dec. Allergy Rhinol (Providence). 2018. PMID: 30027002 Free PMC article.
BACKGROUND: This study evaluated the efficacy of montelukast in reducing seasonal allergic rhinitis symptoms in Japanese children with Japanese cedar (JC) pollinosis induced in an artificial exposure chamber (OHIO Chamber). ...The analysis in a subgroup of subjects who did …
BACKGROUND: This study evaluated the efficacy of montelukast in reducing seasonal allergic rhinitis symptoms in Japanese children wit …
Newer-generation antihistamines and the risk of adverse events in children: A systematic review.
Miligkos M, Dakoutrou M, Statha E, Theochari NA, Mavroeidi IA, Pankozidou Ι, Papaconstadopoulos I, Papadopoulos NG. Miligkos M, et al. Pediatr Allergy Immunol. 2021 Oct;32(7):1533-1558. doi: 10.1111/pai.13522. Epub 2021 May 20. Pediatr Allergy Immunol. 2021. PMID: 33894089
METHODS: We performed a systematic review of randomized controlled trials (RCTs), which included comparisons of safety parameters between an orally administered newer-generation AH and another AH (first- or second-generation), montelukast, or placebo in children aged 12 y …
METHODS: We performed a systematic review of randomized controlled trials (RCTs), which included comparisons of safety parameters between an …
Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.
Liang C, Zhuo P, Zhang Y. Liang C, et al. PLoS One. 2026 Mar 9;21(3):e0343084. doi: 10.1371/journal.pone.0343084. eCollection 2026. PLoS One. 2026. PMID: 41801966 Free PMC article.
METHODS: In this real-world pharmacovigilance study, we collected adverse event (AE) reports of EGPA associated with LTRAs use from the U.S. FDA Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Reporting (JADER), and Canadian Vigilance Adverse Reaction ( …
METHODS: In this real-world pharmacovigilance study, we collected adverse event (AE) reports of EGPA associated with LTRAs use from t …
20 results